TenaTac® - developing an advanced and cost-effective haemostat for the NHS

09 Nov 2021

09:15 - 09:35

Surgical Simulation Theatre

Surgical Simulation

Great innovations don’t always need to drive up procedure costs. TenaTac is a novel haemostat that addresses many of the limitations of existing products, whilst offering to reduce the cost burden on a pressurised NHS. Our data demonstrate that this CE-marked product is more effective than the market leader, whilst avoiding the risks of using blood derived products

Speakers

Paul Hayes, Vascular Surgeon & Chief Medical Officer - Selentus Science

“Future Surgery 2021 will be the first of its kind in the UK, drawing on the work our Commission on the Future of Surgery has done to predict the transformation in the medical care for millions of patients.”
Andrew Reed, Chief Executive of the Royal College of Surgeons of England
“Driven by changes in digital technologies and our fast-evolving understanding of genomics, innovations are expected to affect how we undertake surgery, and how we train surgeons in future.”
Andrew Reed, Chief Executive of the Royal College of Surgeons of England
"Alongside the conference organisers, CloserStill, we aim to deliver a high-quality event that will provide both professional development and discussion space for surgeons and their teams."
Andrew Reed, Chief Executive of the Royal College of Surgeons of England
"We look forward to welcoming colleagues to what promises to be a very high-quality programme and an exciting two days of thought-provoking training and engagement with medical suppliers."
Andrew Reed, Chief Executive of the Royal College of Surgeons of England